Journal of Neurology

, Volume 252, Issue 11, pp 1299–1306

Diagnosis and management of acute movement disorders



Most movement disorders, reflecting degenerative disorders, develop in a slowly progressive fashion. Some movement disorders, however, manifest with an acute onset. We wish to give an overview of the management and therapy of those acute-onset movement disorders.

Drug–induced movement disorders are mainly caused by dopamine–receptor blockers (DRB) as used as antipsychotics (neuroleptics) and antiemetics. Acute dystonic reactions usually occur within the first four days of treatment. Typically, cranial pharyngeal and cervical muscles are affected. Anticholinergics produce a prompt relief.Akathisia is characterized by an often exceedingly bothersome feeling of restlessness and the inability to remain still. It is a common side effect of DRB and occurs within few days after their initiation. It subsides when DRB are ceased.Neuroleptic Malignant Syndrome is a rare, but life–threatening adverse reaction to DRB which may occur at any time during DRB application. It is characterised by hyperthermia, rigidity, reduced consciousness and autonomic failure. Therapeutically immediate DRB withdrawal is crucial.Additional dantrolene or bromocriptine application together with symptomatic treatment may be necessary.

Paroxysmal dyskinesias are childhood onset disorders characterised by dystonic postures, chorea, athetosis and ballism occurring at irregular intervals. In Paroxysmal Kinesigenic Dyskinesia they are triggered by rapid movements, startle reactions or hyperventilation. They last up to 5 minutes, occur up to 100 times per day and are highly sensitive to anticonvulsants. In Paroxysmal Non–Kinesiogenic Dyskinesia they cannot be triggered, occur less frequently and last longer.Other paroxysmal dyskinesias include hypnogenic paroxysmal dyskinesias, paroxysmal exertional dyskinesia, infantile paroxysmal dystonias, Sandifer's syndrome and symptomatic paroxysmal dyskinesias.

In Hereditary Episodic Ataxia Type 1 attacks of ataxia last for up to two minutes, may be accompanied by dysarthria and dystonia and usually respond to phenytoin. In Type 2 they can last for several hours, may be accompanied by vertigo, headache and malaise and usually respond to acetazolamide. Symptomatic episodic ataxias can occur in a number of metabolic disorders, but also in multiple sclerosis and Behcet's disease.

Key words

movement disorders drug–induced dopamine receptor blockade acute dystonic reaction neuroleptic malignant syndrome akathisia paroxysmal dyskinesias episodic ataxias 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Addonizio G, Susman VL, Roth SD (1987) Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 22:1004–1020CrossRefPubMedGoogle Scholar
  2. 2.
    Akman–Demir FG, Eraksoy M, Gurvit IH, Saruhan–Direskeneli G, Aral O (1995) Paroxysmal dysarthria and ataxia in a patient with Behcet's disease. J Neurol 242:344–347PubMedCrossRefGoogle Scholar
  3. 3.
    Angelini L, Rumi V, Lamperti E, Nardocci N (1988) Transient paroxysmal dystonia in infancy. Neuropediatrics 19:171–174PubMedGoogle Scholar
  4. 4.
    Auburger G, Ratzlaff T, Lunkes A, Nelles HW, Leube B, Binkofski F, Kugel H, Heindel W, Seitz R, Benecke R, Witte OW, Voit T (1996) A gene for autosomal dominant paroxysmal choreoathetosis/ spasticity (CSE) maps to the vicinity of a potassium channel gene cluster on chromosome 1p, probably within 2 cM between D1S443 and D1S197. Genomics 31:90–94CrossRefPubMedGoogle Scholar
  5. 5.
    Ayd FJ Jr (1961) A survey of drug–induced extrapyramidal reactions. JAMA 175:1054–1060PubMedGoogle Scholar
  6. 6.
    Bain PG, Larkin GB, Calver DM, O'Brien MD (1991) Persistent superior oblique paresis as a manifestation of familial periodic cerebellar ataxia. Br J Ophthalmol 75:619–621PubMedCrossRefGoogle Scholar
  7. 7.
    Bain PG, O'Brien MD, Keevil SF, Porter DA (1992) Familial periodic cerebellar ataxia: a problem of cerebellar intracellular pH homeostasis. Ann Neurol 31:147–154CrossRefPubMedGoogle Scholar
  8. 8.
    Baron DN, Dent CE, Harris H, Hart EW, Jepson JB (1956) Hereditary pellagra– like skin rash with temporary cerebellar ataxia, constant renal amino–aciduria, and other bizarre biochemical features. Lancet 271(6940):421–428PubMedCrossRefGoogle Scholar
  9. 9.
    Bateman DN, Darling WM, Boys R, Rawlins MD (1989) Extrapyramidal reactions to metoclopramide and prochlorperazine. Q J Med 264:307–311Google Scholar
  10. 10.
    Berardi D, Amore M, Keck PE Jr, Troia M, Dell'Atti M (1998) Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case control study. Biol Psychiatry 44:748–754CrossRefPubMedGoogle Scholar
  11. 11.
    Blaisdell GD (1994) Akathisia: a comprehensive review and treatment summary. Pharmacopsychiatry 27:139–146PubMedCrossRefGoogle Scholar
  12. 12.
    Blass JP, Avigan J, Uhlendorf BW (1970) A defect in pyruvate decarboxylase in a child with an intermittent movement disorder. J Clin Invest 49:423–432PubMedCrossRefGoogle Scholar
  13. 13.
    Boyer WF, Bakalar NH, Lake CR (1987) Anticholinergic prophylaxis of acute haloperidol–induced acute dystonic reactions. J Clin Psychopharmacol 7:164–166PubMedGoogle Scholar
  14. 14.
    Braude WM, Barnes TR, Gore SM (1983) Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 143:139–150PubMedCrossRefGoogle Scholar
  15. 15.
    Brody AL (1996) Acute dystonia induced by rapid increase in risperidone dosage. J Clin Psychopharmacol 16:461–462CrossRefPubMedGoogle Scholar
  16. 16.
    Caroff SN, Mann SC (1993) Neuroleptic malignant syndrome. Med Clin North Am 77:185–202PubMedGoogle Scholar
  17. 17.
    Chong SA, Tan CH (1996) Fluvoxamine and akathisia. J Clin Psychopharmacol 16:334–335CrossRefPubMedGoogle Scholar
  18. 18.
    Dancis J, Hutzler J, Rokkones T (1967) Intermittent branched–chain ketonuria. Variant of maple–syrup–urine disease. N Engl J Med 276:84–89PubMedCrossRefGoogle Scholar
  19. 19.
    Daras M, Koppel BS, Atos–Radzion E (1994) Cocaine–induced choreoathetoid movements ('crack dancing'). Neurology 44:751–752PubMedGoogle Scholar
  20. 20.
    Delay J, Pichot P, Lemperiere T, Elissade B, Peigne F (1960) Un neuroleptique majeur non–phenothiazine et non reserpinique, l'haloperidol, dans le traitement des psychoses. Annales Medico–Psychologique 118:145–152Google Scholar
  21. 21.
    Demirkiran M, Jankovic J (1995) Paroxysmal dyskinesias: Clinical features and classification. Ann Neurol 38:571–579CrossRefPubMedGoogle Scholar
  22. 22.
    Dickey W (1991) The neuroleptic malignant syndrome. Prog Neurobiol 36:425–436CrossRefPubMedGoogle Scholar
  23. 23.
    Duvoisin RC, Yahr MD (1965) Encephalitis and Parkinsonism. Arch Neurol 12:227–239PubMedGoogle Scholar
  24. 24.
    Fahn S (1994) The paroxysmal dyskinesias. In:Marsden CD, Fahn S (eds) Movement Disorders 3. Butterworth–Heinemann, Oxford, pp 310–345Google Scholar
  25. 25.
    Fink JK, Rainer S, Wilkowski J, Jones SM, Kume A, Hedera P, Albin R, Mathay J, Girbach L, Varvil T, Otterud B, Leppert M (1996) Paroxysmal dystonic choreoathetosis: tight linkage to chromosome 2q. Am J Hum Genet 59:140–145PubMedGoogle Scholar
  26. 26.
    Fouad GT, Servidei S, Durcan S, Bertini E, Ptacek LJ (1996) A gene for familial paroxysmal dyskinesia (FPD1) maps to chromosome 2q. Am J Hum Genet 59:135–139PubMedGoogle Scholar
  27. 27.
    Gancher ST, Nutt JG (1986) Autosomal dominant episodic ataxia: a heterogeneous syndrome. Mov Disord 1:239–253CrossRefPubMedGoogle Scholar
  28. 28.
    Garver DL, Davis DM, Dekirmenjian H, Ericksen S, Gosenfeld L, Haraszti J (1976) Dystonic reactions following neuroleptics: time course and proposed mechanisms. Psychopharmacologia 47:199–201CrossRefPubMedGoogle Scholar
  29. 29.
    Gibb WR, Lees AJ (1986) The clinical phenomenon of akathisia. J Neurol Neurosurg Psychiatry 49:861–866PubMedCrossRefGoogle Scholar
  30. 30.
    Gill J, Singh H, Nugent K (2003) Acute lithium intoxication and neuroleptic malignant syndrome. Pharmacotherapy 23:811–815PubMedCrossRefGoogle Scholar
  31. 31.
    Gorard DA, Gibberd FB (1989) Paroxysmal dysarthria and ataxia: associated MRI abnormality. J Neurol Neurosurg Psychiatry 52:1444–1445PubMedGoogle Scholar
  32. 32.
    Gowers WR (1885) Epilepsy and Other Chronic Convulsive Diseases. Their Cause, Symptoms, and Treatment. Dover, New York (reprint of 1885 edition), 1964:75–76Google Scholar
  33. 33.
    Homan RW, Vasko MR, Blaw M (1980) Phenytoin plasma concentrations in paroxysmal kinesigenic choreoathetosis. Neurology 30:673–676PubMedGoogle Scholar
  34. 34.
    Horner FH, Jackson LC (1969) Familial paroxysmal choreoathetosis. In: Barbeau A, Brunette JR (eds) Progress in Neuro–Genetics. Excerpta Medica Foundation, Amsterdam, pp 745–751Google Scholar
  35. 35.
    Kastrup O, Gastpar M, Schwarz M (1994) Acute dystonia due to clozapine. J Neurol Neurosurg Psychiatry 57:119PubMedGoogle Scholar
  36. 36.
    Kertesz A (1967) Paroxysmal kinesigenic choreoathetosis. An entity within the paroxysmal choreoathetosis syndrome. Description of 10 cases, including 1 autopsied. Neurology 17:680–690PubMedGoogle Scholar
  37. 37.
    Lance JW (1977) Familial paroxysmal dystonic choreoathetosis and its differentiation from related syndromes. Ann Neurol 2:285–293CrossRefPubMedGoogle Scholar
  38. 38.
    Lang AE, Johnson K (1987) Akathisia in idiopathic Parkinson's disease. Neurology 37:477–481PubMedGoogle Scholar
  39. 39.
    Litt M, Kramer P, Browne D, Gancher S, Brunt ER, Root D, Phromchotikul T, Dubay CJ, Nutt J (1994) A gene for episodic ataxia/myokymia maps to chromosome 12p13. Am J Hum Genet 55:702–709PubMedGoogle Scholar
  40. 40.
    Lopez–Alemany M, Ferrer–Tuset C, Bernacer–Alpera B (1997) Akathisia and acute dystonia induced by sumatriptan. J Neurol 244:131–132PubMedCrossRefGoogle Scholar
  41. 41.
    Lugaresi E, Cirignotta F (1981) Hypnogenic paroxysmal dystonia: epileptic seizure or a new syndrome? Sleep 4:129–138PubMedGoogle Scholar
  42. 42.
    Lugaresi E, Cirignotta F, Montagna P (1986) Nocturnal paroxysmal dystonia. J Neurol Neurosurg Psychiatry 49:375–380PubMedGoogle Scholar
  43. 43.
    Marsden CD, Jenner P (1980) The pathophysiology of extrapyramidal side–effects of neuroleptic drugs. Psychol Med 10:55–72PubMedCrossRefGoogle Scholar
  44. 44.
    Mazurek MF, Rosebush PI (1996) Circadian pattern of acute, neurolepticinduced dystonic reactions. Am J Psychiatry 153:708–710PubMedGoogle Scholar
  45. 45.
    Miller CH, Hummer M, Oberbauer H, Kurzthaler I, DeCol C, Fleischhacker WW (1997) Risk factors for the development of neuroleptic induced akathisia. Eur Neuropsychopharmacol 7:51–55CrossRefPubMedGoogle Scholar
  46. 46.
    Mount LA, Reback S (1940) Familial paroxysmal choreoathetosis. Arch Neurol Psychiat 44:841–847Google Scholar
  47. 47.
    Nonino F, Campomori A (1999) Neuroleptic malignant syndrome associated with metoclopramide. Ann Pharmacother 33:644–645PubMedCrossRefGoogle Scholar
  48. 48.
    Plant G (1983) Focal paroxysmal kinesigenic choreoathetosis. J Neurol Neurosurg Psychiatry 46:345–348PubMedGoogle Scholar
  49. 49.
    Poyurovsky M, Meerovich I, Weizman A (1995) Beneficial effect of low–dose mianserin on fluvoxamine–induced akathisia in an obsessive–compulsive patient. Int Clin Psychopharmacol 10:111–114PubMedGoogle Scholar
  50. 50.
    Raja M, Azzoni A (2001) Novel antipsychotics and acute dystonic reactions. Int J Neuropsychopharmacol 4:393–397PubMedCrossRefGoogle Scholar
  51. 51.
    Rosenberg MR, Green M (1989) Neuroleptic malignant syndrome. Review of response to therapy. Arch Intern Med 149:1927–1931CrossRefPubMedGoogle Scholar
  52. 52.
    Rupniak NM, Jenner P, Marsden CD (1986) Acute dystonia induced by neuroleptic drugs. Psychopharmacology (Berl) 88:403–419 CrossRefPubMedGoogle Scholar
  53. 53.
    Sachdev P, Kruk J (1994) Clinical characteristics and predisposing factors in acute drug–induced akathisia. Arch Gen Psychiatry 51:963–974PubMedGoogle Scholar
  54. 54.
    Sakkas P, Davis JM, Janicak PG, Wang ZY (1991) Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull 27:381–384PubMedGoogle Scholar
  55. 55.
    Shahnawaz M, van der Westhuizen LR, Gledhill RF (2001) Episodic cervical dystonia associated with gastro–oesophageal reflux. A case of adult–onset Sandifer syndrome. Clin Neurol Neurosurg 103:212–215CrossRefPubMedGoogle Scholar
  56. 56.
    Shalev A, Hermesh H, Munitz H (1988) The role of external heat load in triggering the neuroleptic malignant syndrome. Am J Psychiatry 145:110–111PubMedGoogle Scholar
  57. 57.
    Shen WW (1981) Akathisia: an overlooked, distressing, but treatable condition. J Nerv Ment Dis 169:599–600PubMedGoogle Scholar
  58. 58.
    Sicard JA (1923) Akathisia and tasikinesia. Presse Med (Paris) 31:265–266Google Scholar
  59. 59.
    Simpson GM, Lindenmayer JP (1997) Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 17:194–201PubMedCrossRefGoogle Scholar
  60. 60.
    Snyder CH (1969) Paroxysmal torticollis in infancy. Am J Dis Child 117:458–460PubMedGoogle Scholar
  61. 61.
    Susman VL, Addonizio G (1988) Recurrence of neuroleptic malignant syndrome. J Nerv Ment Dis 176:234–241PubMedCrossRefGoogle Scholar
  62. 62.
    Swett C Jr (1975) Drug–induced dystonia. Am J Psychiatry 132:532–534PubMedGoogle Scholar
  63. 63.
    Thornberg SA, Ereshefsky L (1993) Neuroleptic malignant syndrome associated with clozapine monotherapy. Pharmacotherapy 13:510–514PubMedGoogle Scholar
  64. 64.
    Vaamonde J, Artieda J, Obeso JA (1991) Hereditary paroxysmal ataxia with neuromyotonia. Mov Disord 6:180–182CrossRefPubMedGoogle Scholar
  65. 65.
    Velamoor VR, Norman RM, Caroff SN, Mann SC, Sullivan KA, Antelo RE (1994) Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis 182:168–173PubMedCrossRefGoogle Scholar
  66. 66.
    Von Brederlow B, Hahn AF, Koopman WJ, Ebers GC, Bulman DE (1995) Mapping the gene for acetazolamide responsive hereditary paroxysmal cerebellar ataxia to chromosome 19p. Hum Mol Genet 4:279–284PubMedCrossRefGoogle Scholar
  67. 67.
    Wang HC, Hsieh Y (2001) Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy. Mov Disord 16:765–767CrossRefPubMedGoogle Scholar
  68. 68.
    Washington C, Haines KA, Tam CW (1989) Amoxapine–induced neuroleptic malignant syndrome. DICP 23:713PubMedGoogle Scholar
  69. 69.
    Weiner WJ, Lang AE (1989) Movement Disorders: A Comprehensive Survey. Futura Publishing, Mout Kisco, New York, pp 582–583Google Scholar
  70. 70.
    Weller M, Kornhuber J (1992) A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. Med Hypotheses 38:329–333CrossRefPubMedGoogle Scholar

Copyright information

© Steinkopff-Verlag 2005

Authors and Affiliations

  1. 1.Dept. of NeurologyRostock UniversityRostockGermany

Personalised recommendations